oasis 1 oral semaglutide 50 mg obesity nejm 2023 taken once per day in adults with overweight or (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial oral semaglutide 50 mg obesity

People on the drug often report feeling full sooner and experiencing decreased hunger between meals

Ferroptosis is controlled by the coordinated transcriptional regulation of glutathione and labile iron metabolism by the transcription factor BACH1

An initial analysis of the FDA adverse event reporting system (FAERS) data demonstrated no consistent trends in DKA with SGLT2i use over time [39], however an alternative cohort study of 50,220 individuals with type 2 diabetes showed the highest risk of DKA shortly after SGLT2i initiation, which subsequently reduced with time [40]

A small note on air bubble anxiety: subcutaneous air bubbles are not dangerous

In fact, I am enjoying sports now more than ever